E-viri
Recenzirano
Odprti dostop
-
Chang, Elaine; Hahn, Noah M.; Lerner, Seth P.; Fallah, Jaleh; Agrawal, Sundeep; Kamat, Ashish M.; Bhatnagar, Vishal; Svatek, Robert S.; Jaigirdar, Adnan A.; Bross, Peter; Shore, Neal; Kates, Max; Sachse, Karen; Brewer, Jamie R.; O’Donnell, Michael A.; Steinberg, Gary D.; Viviano, Charles J.; Bloomquist, Erik; Ribal, Maria J.; Galsky, Matthew D.; Oliver, Richard; Black, Peter C.; Al-Ahmadie, Hikmat; Brothers, Kenneth; Pohar, Kamal; Dinney, Colin P.; Feng, Zhou; Downs, Tracy M.; Porten, Sima P.; Smith, Angela B.; Bangs, Rick; Psutka, Sarah P.; Agarwal, Neeraj; Amiri-Kordestani, Laleh; Suzman, Daniel L.; Pazdur, Richard; Kluetz, Paul G.; Weinstock, Chana
Bladder cancer, 09/2023, Letnik: 9, Številka: 3Journal Article
BACKGROUND: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus Calmette-Guerin (BCG) supply issues underscore the importance of developing safe and effective drugs for NMIBC. OBJECTIVE: On November 18–19, 2021, the FDA held a public virtual workshop to discuss NMIBC research needs and potential trial designs for future development of effective therapies. METHODS: Representatives from various disciplines including urologists, oncologists, pathologists, statisticians, basic and translational scientists, and the patient advocacy community participated. The workshop format included invited lectures, panel discussions, and opportunity for audience discussion and comment. RESULTS: In a pre-workshop survey, 92% of urologists surveyed considered the development of alternatives to BCG as a high drug development priority for BCG-naïve high-risk patients. Key topics discussed included definitions of disease states; trial design for BCG-naïve NMIBC, BCG-unresponsive carcinoma in situ, and BCG-unresponsive papillary carcinoma; strengths and limitations of single-arm trial designs; assessing patient-reported outcomes; and considerations for assessing avoidance of cystectomy as an efficacy measure. CONCLUSIONS: The workshop discussed several important opportunities for trial design refinement in NMIBC. FDA encourages sponsors to meet with the appropriate review division to discuss trial design proposals for NMIBC early in drug development.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.